Coagulation Defects
Conditions
Keywords
Entegrion, Spray-dried Solvent/Detergent Plasma, Fresh Frozen Plasma, Transfusion, Resuscitation, Hemorrhage, Coagulopathy
Brief summary
This study is a Phase 1, single-center, open-label, ascending dose study which will assess the safety and tolerability of 5 doses of spray-dried solvent/detergent treated plasma (Resusix®) in healthy volunteers.
Interventions
BIOLOGICALSpray-dried S/D-treated Plasma
Infusion of 100 mL Spray-dried S/D-treated Plasma
DRUGSpray-dried S/D-treated plasma
Infusion of 200mL Spray-dried S/D-treated plasma
Sponsors
Entegrion, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subject must provide written informed consent for participation in this study and valid contact information. 2. Subject must be a male or postmenopausal female. 3. Subject must be at least 18 years of age and not older than 55 years of age. 4. Subject must be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening, including no history or symptoms of respiratory or cardiac disease. 5. Vital signs should be within normal limits at Screening: 1. Body temperature within 97°F to 99°F 2. Heart rate 45 to 100 beats per minute (bpm) 3. Systolic blood pressure (SBP) within 90 to 140 mmHg and DBP within 50 to 90 mmHg. 6. Subject must have a normal (no clinically significant abnormality) EKG at Screening and prior to administration of Resusix 1. PR interval within 120 and 200 mm/s 2. QRS interval \<120 mm/s 3. QTc interval ≤440 mm/s 7. Subject must have laboratory hematology values within following normal ranges: 1. White blood cell count (WBC): 4,500 to 11,000/mL 2. Platelet (PLT) count: 150,000 to 400,000/mL; 3. Hemoglobin (Hb): 12.5 to 15.5 g/dL; 4. Activated partial thromboplastin time (aPTT): 24.6 to 36.7 seconds; 5. Normal PT, International Normalized Ratio (INR): 0.8 to 1.2; 6. Protein C ≥90%, Protein S ≥77%; 7. Antithrombin III levels (ATIII) ≥100%. 8. Subject must have laboratory clinical chemistry values within normal range specified by the testing laboratory. 9. BMI ≤30 kg/m2. 10. Subject must have a negative toxicology screening panel (urine test including qualitative identification of PCP, barbiturates, THC, amphetamines, benzodiazepines, opiates, and cocaine.) 11. Subject must be a non-drinker (≤2 alcoholic beverages per week) and a non-smoker (any tobacco products within six months prior to Screening). 12. Subject must have no history of recreational (including IV) drug use (by self-declaration). 13. Subject must have the ability and willingness to attend frequent visits to the study center.
Exclusion criteria
1. Subject with lower extremity deep vein thrombosis (DVT) at Screening. 2. Subject has a history of coagulopathy or thromboembolic disease. 3. Subject has a first degree family member with history of venous thromboembolic disease \<55 years of age or arterial thromboembolic disease \<45 years of age. 4. Subject has documented drug allergies with well-described reactions. 5. Subject has hepatomegaly, splenomegaly, adenopathy, bruising, and/or ecchymoses identified at Screening. 6. Subject is found to have positive NAT test for HIV, HBV or HCV. 7. Subject has any murmurs, rubs, or gallops on cardiac auscultation. 8. Subject has had a previous transfusion at any time. 9. Subject is unlikely to comply with the study protocol or, in the opinion of the investigator, would not be a suitable candidate for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-emergent SAEs | 12 weeks | Incidence of treatment-emergent SAEs reported for up to 12 weeks post Resusix infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline of select coagulation factors | 30 minutes post infusion | To evaluate the recovery of select coagulation factors after infusion of 2 Resusix |
| Incidence of AEs | 12 weeks | To evaluate the incidence of AEs for up to 12 weeks after infusion of Resusix |
Countries
United States
Outcome results
None listed